Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated (PRLD) Revenue
Annual & quarterly revenue history · segment & region breakdown
PRLD · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsPrelude Therapeutics Incorporated trailing twelve-month (TTM) revenue is $0.02B, an increase of 73.43% year-over-year from $0.01B in FY2025.
Revenue trend
2025 – 2018 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.01B | +$0.01B | +73.43% |
| 2024-12-31 | $0.01B | +$0.01B | — |
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Prelude Therapeutics Incorporated receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Prelude Therapeutics Incorporated reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Prelude Therapeutics Incorporated's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
PRLD revenue · 4 questionsPRLD's trailing twelve-month (TTM) revenue is $0.02B. That is an increase of 73.43% year-over-year from $0.01B in FY2025.
▸ Source: FMP · Prelude Therapeutics Incorporated SEC filings · GAAP · Prelude Therapeutics Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026